anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this study, the performance with the CI is investigated over time in three groups of freshly implanted CI users. The first group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9. In the second group of users, an anatomy-based frequency distribution is used as per anatomy-based fitting in MAESTRO 9. The performance with anatomy-based fitting is assessed by comparing performance with the CI in these two groups over time.

The third group constitutes the within-subject design. These subjects are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
Short bowel syndrome may result from extensive resection of the small bowel. Because the transport of bile salts, cobalamin (vitamin B 12 ), and cholesterol is localized to the ileum, resection of this region is poorly tolerated. Patients who have had their ileum resected cannot absorb cholesterol, long chain fatty acids, fat soluble vitamins (A, D, E, and K), cobalamin (vitamin B 12 ), and the metal ions (Ca 2+ , Mg 2+ , and Zn 2+ ). Liposomes are suitable biological vehicles for the non-parenteral delivery of these fat and water soluble nutrients directly into the blood of patients with the small bowel syndrome. Liposomes are compartmentalized vesicles consisting of bilayer lipids enclosing aqueous chambers. The lipid and water soluble nutrients can be commercially packaged in their respective compartments and delivered directly into the blood stream of these patients, thereby bypassing the intestines. The liposomes can pass through water barriers. Their solubility in lipid rich surface membranes permits the release of the enclosed nutrients and their diffusion into the interior of cells.
Week 1 (at recovery from surgery; ≥ 6 weeks post-surgery)-Priming Vaccine dose; no chemokine modulation; 1 day: αDC1 vaccine; Oral celecoxib, 200 mg, before \& after treatment on day of vaccination; Weeks 2-3 -Rest; Week 4 (target) - Booster C1; Mon: αDC1 vaccine;Tues - Fri: Systemic Chemokine Modulation Regimen. Oral celecoxib, 200 mg, BID on vaccination days \& CKM. Celecoxib will be dced after CKM on Fri. Rintatolimod only administered on Wed \& Fri.; Week 5-7 -Rest; Week 8 (target) -Booster C2; Monday: αDC1 vaccine. Oral celecoxib, 200 mg, BID on days of vaccination and CKM. Tues - Fri:Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed \& Fri. Celecoxib will be dced after CKM on Fri.; Week 9-11 -Rest; Week 12 (target) -Booster C3; Monday: αDC1 vaccine. Tues-Fri: Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed \& Fri. Oral celecoxib, 200 mg, BID, given on days of vaccination and CKM. Celecoxib will be discontinued after CKM on Fri.
No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III). Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors).  In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving candesartan and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors.

Lithium

Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists. An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
Proper protein folding relies on the assistance of molecular chaperones post-translation. Dysfunctions in chaperones can cause diseases associated with protein misfolding, including cancer. While previous studies have identified CCT2 as a chaperone subunit and an autophagy receptor, its specific involvement in glioblastoma remains unknown. Here, we identified CCT2 promote glioblastoma progression. Using approaches of coimmunoprecipitation, mass spectrometry and surface plasmon resonance, we found CCT2 directly bound to KRAS leading to increased stability and upregulated downstream signaling of KRAS. Interestingly, we found that dihydroartemisinin, a derivative of artemisinin, exhibited therapeutic effects in a glioblastoma animal model. We further demonstrated direct binding between dihydroartemisinin and CCT2. Treatment with dihydroartemisinin resulted in decreased KRAS expression and downstream signaling. Highlighting the significance of CCT2, CCT2 overexpression rescued the inhibitory effect of dihydroartemisinin on glioblastoma. In conclusion, the study demonstrates that CCT2 promotes glioblastoma progression by directly binding to and enhancing the stability of the KRAS protein. Additionally, dihydroartemisinin inhibits glioblastoma by targeting the CCT2 and the following KRAS signaling. Our findings overcome the challenge posed by the undruggable nature of KRAS and offer potential therapeutic strategies for glioblastoma treatment.
Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
Pregnancy Category C.

There are no adequate and well-controlled trials of EPIVIR-HBV in pregnant women. Because animal reproduction studies are not always predictive of human response, EPIVIR-HBV should be used during pregnancy only if the potential benefits outweigh the potential risks to the fetus. 

Antiretroviral Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to lamivudine, a Pregnancy Registry has been established. Healthcare providers are encouraged to register patients by calling 1-800-258-4263.

Animal Data: Animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. Reproduction studies have been performed in rats and rabbits at orally administered doses up to 4,000 mg/kg/day and 1,000 mg/kg/day, respectively, producing plasma levels up to approximately 60 times that for the adult HBV dose. Evidence of early embryolethality was seen in the rabbit at exposure levels similar to those observed in humans, but there was no indication of this effect in the rat at exposure levels up to 60 times those in humans. 

Studies in pregnant rats and rabbits showed that lamivudine is transferred to the fetus through the placenta.
Patients with LR3 observations would undergo CEUS and AMRI every 6 months; patients with LR4 observations would undergo CEUS and AMRI 3 months after enrollment and every 6 months thereafter. CEUS and AMRI will preferably be done the same day to minimize burden on the patient, although will be permitted to be completed within 14 days of each other. This interval is sufficiently short to minimize the chance of intervening events. AMRI and CEUS will be performed every 3-6 months until HCC development, regression to LR-1 or LR-2 (i.e., definitely or likely benign, respectively), or end of follow-up at 24 months post-enrollment.
Described herein is a host cell comprising a nucleic acid encoding a bispecific protein, and/or a vector comprising a nucleic acid encoding a bispecifc protein. The bispecific protein comprises (a) a polypeptide comprising an amino acid sequence having the formula A-L1-P-L2-P, and, (b) an immunoglobulin light chain of an IgG antibody. A is an immunoglobulin heavy chain of an IgG antibody, L1 is a first peptide linker that is absent or is 3 to 40 amino acids long, P is a BAFF-binding peptide that is 10 to 40 amino acids long, and L2 is a second peptide linker that is absent or is 5 to 50 amino acids long. The immunoglobulin heavy chain of (a) and the immunoglobulin light chain of (b) form an IgG antibody, comprising two molecules of the polypeptide of (a) and two molecules of the light chain of (b), that can bind B7RP1. The protein can inhibit BAFF-mediated proliferation of human B cells, and B7RP1-mediated proliferation of human T cells. The host cell is a bacterial cell, a yeast cell, an insect cell, a plant cell, or a mammalian cell.
The SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants receive automated self-management support messages for symptoms reported and a Nurse Practitioner monitors and responds to alerts for COVID-19 symptoms and poorly controlled or worsening cancer symptoms. Participants in this group complete baseline and monthly measures.
NEW MATERIAL:A compound shown by the formulaI(R<1> is 1-4C alkyl, or phenyl; R<2> is 1-4C alkyl). USE:A drug, agricultural chemical and an intermediate for them. PROCESS:A compound shown by the formula II is reacted with phosgene or chloroformic trichloromethyl ester in a solvent, preferably sufficiently anhydrous aromatic hydrocarbon, halogenated hydrocarbon, etc. in the presence of pyridine at -20-40 deg.C for 1-30hr, to give a compound shown by the formulaI. The amount of pyridine used is preferably 2mol based on 1mol phsogene and 4mol based on 1mol chloroformic trichloromethyl ester. The amount of the compound shown by the formula II used is preferably 0.4-1mol based on 1mol phosgene and 0.2-0.5mol based on 1mol chloroformic trichloromethyl ester.
Family-based obesity management interventions targeting child, adolescent and parental lifestyle behaviour modifications have shown promising results. Further intervening on the family system may lead to greater improvements in obesity management outcomes due to the broader focus on family patterns and dynamics that shape behaviours and health. This review aimed to summarize the scope of pediatric obesity management interventions informed by family systems theory (FST). Medline, Embase, CINAHL and PsycInfo were searched for articles where FST was used to inform pediatric obesity management interventions published from January 1980 to October 2023. After removal of duplicates, 6053 records were screened to determine eligibility. Data were extracted from 50 articles which met inclusion criteria; these described 27 unique FST-informed interventions. Most interventions targeted adolescents (44%), were delivered in outpatient hospital settings (37%), and were delivered in person (81%) using group session modalities (44%). Professionals most often involved were dieticians and nutritionists (48%). We identified 11 FST-related concepts that guided intervention components, including parenting skills, family communication, and social/family support. Among included studies, 33 reported intervention effects on at least one outcome, including body mass index (BMI) (n = 24), lifestyle behaviours (physical activity, diet, and sedentary behaviours) (n = 18), mental health (n = 12), FST-related outcomes (n = 10), and other outcomes (e.g., adiposity, cardiometabolic health) (n = 18). BMI generally improved following interventions, however studies relied on a variety of comparison groups to evaluate intervention effects. This scoping review synthesises the characteristics and breadth of existing FST-informed pediatric obesity management interventions and provides considerations for future practice and research.
With gambling becoming more accessible, the occurrence of problems related to gambling are on the rise. The costs of problem gambling are enormous.There are social and economic costs, the gambler can sometimes lose a significant relationship, job, or commit an illegal activity. Pathological gamblers are also at risk for developing a general medical condition related to stress. There is a high risk of suicide and problem gamblers also have increased rates of mental health disorders. Relatively few people choose to attend formal treatment programs so it's important to provide a range of options to make treatment more accessible. The present study examines the effectiveness of minimal and brief interventions delivered by the telephone.

Comparison(s): The "Workbook Only Control" condition involves receiving the self-help booklet through the mail after a brief telephone assessment. The "Minimal Treatment" condition involves receiving the same workbook but also having a motivational enhancement intervention by telephone. The "Brief Treatment" condition provides the workbook, motivational enhancement, and follow-up support on six occasions spread over 36 weeks. The "Wait List Control" condition involves participants being assigned to a six week waiting list. Participants are assessed and after a six week waiting period they will have a reassessment at which time they will be sent the gambling self-help workbook.
The invention provides the use of mitoxantrone hydrochloride liposomes and peginase in the manufacture of a medicament for the treatment of NK/T cell lymphoma (NKTCL). The NKTCL includes primary, recurrent, refractory extranodal NKTCL. Preferably, the primary, recurrent, refractory extranodal NKTCL is primary, recurrent, refractory extranodal nasal NK/T cell lymphoma. Other first-line and second-line drugs for treating NKTCL can be further used on the basis of the above. The invention also provides a method of treating NKTCL by administering to a patient therapeutically effective amounts of mitoxantrone hydrochloride liposomes and peginase. The mitoxantrone liposome further improves the curative effect of the peginase on NKTCL, has small toxic and side effects, improves the disease remission rate, particularly improves the complete remission rate (CR rate) and partial remission rate (PR rate) of the disease, can control the progress of the disease, comprehensively evaluates the risk prediction of adverse reaction, and benefits more than the risk.
A water-soluble hormonous substance, applicable in the treatment of cancerous tumour and gynecological disorders, is prepared by extracting umbilical cord tissue, or the eggs of birds, reptiles, or fish, with boiling water and treating the filtered and evaporated extract with organic solvents, such as alcohol, ether, or acetone, to remove impurities.  For example a porcine umbilical cord is tied at each end, washed in water and drained of blood by flowing water through glass tubes inserted in the blood vessels.  The cord is then dried, not above 100 DEG  C., and ground to powder.  Twenty grms. of the product is boiled for about one hour with 500 c.c. of distilled water, filtered, and the filtrate evaporated.  The residue is extracted for five or six days with 100 c.c. of a mixture of equal parts of ether and acetone, filtered, and the filtration residue dissolved in 100 c.c. of water and again filtered.  To the filtrate is added 150 c.c. of pure alcohol which, in twenty-four hours, throws down albuminous substances.  The last purification step may be repeated several times.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel modifications A or A' of compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazol-4-carboxamide characterized by lines corresponding to interplanar spaces (values d) by data of powder X-ray diffraction analysis and a pharmaceutical composition. Crystalline modification A is thermodynamically stable form at the room temperature and at higher temperatures also. Modification A' shows the same crystalline structure as modification A but it shows defects in crystalline lattice. Compounds exhibit anticonvulsive activity. EFFECT: valuable medicinal properties of compounds. 10 cl, 2 tbl, 2 dwg
Methenamine hippurate tablets, USP are available as 1 g oval shaped, scored and peach colored tablets. Chemically, methenamine hippurate is Hexamethylene-tetramine monohippurate. The molecular formula of methenamine hippurate is C H N O and molecular weight is 319.36. Its structural formula is: 152153

Each methenamine hippurate tablets, USP intended for oral administration contains 1 g of methenamine hippurate. In addition, it also contains the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, povidone K29/32, saccharin sodium and FD&C Yellow #6 Aluminum Lake as a color additive.

Meets USP Dissolution Test 2.
Patients with chronic kidney disease and a glomerular filtration rate less than 60 ml/min of creatinine. Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
Arm A: ADT + Intensity-Modulated Image-Guided Radiation Therapy + Darolutamide ADT will be associated with LHRH agonists or antagonists for 24 months4. Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
Vitamin D3 (cholecalciferol) will be administered orally at a dose of 10,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 50,000 IU weekly for patients weighing 50 kg or greater.
Group 1, pt 0-20: daily application of 5 grams (with applicator) for 1 month. Followed by weekly applications (5 grams withapplicator) for 5 months.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality globally and the risk of developing lung cancer is six times greater in individuals with COPD who smoke compared to those who do not smoke. Matrix metalloproteinases (MMPs) play a crucial role in the pathophysiology of respiratory diseases by promoting inflammation and tissue degradation. Furthermore, MMPs are involved in key processes like epithelial-to-mesenchymal transition (EMT), metastasis, and invasion in lung cancer. While EMT has traditionally been associated with the progression of lung cancer, recent research highlights its active involvement in individuals with COPD. Current evidence underscores its role in orchestrating airway remodeling, fostering airway fibrosis, and contributing to the potential for malignant transformation in the complex pathophysiology of COPD. The precise regulatory roles of diverse MMPs in steering EMT during COPD progression needs to be elucidated. Additionally, the less-understood aspect involves how these MMPs bi-directionally activate or regulate various EMT-associated signaling cascades during COPD progression. This review article explores recent advancements in understanding MMPs' role in EMT during COPD progression and various pharmacological approaches to target MMPs. It also delves into the limitations of current MMP inhibitors and explores novel, advanced strategies for inhibiting MMPs, potentially offering new avenues for treating respiratory diseases.
Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
Intestinal permeabilization is central to the pathophysiology of chronic gut inflammation. This study investigated the efficacy of glucoraphanin (GR), prevalent in cruciferous vegetables, particularly broccoli, and its derivative sulforaphane (SF), in inhibiting tumor necrosis factor alpha (TNFα)-induced Caco-2 cell monolayers inflammation and permeabilization through the regulation of redox-sensitive events. TNFα binding to its receptor led to a rapid increase in oxidant production and subsequent elevation in the mRNA levels of NOX1, NOX4, and Duox2. GR and SF dose-dependently mitigated both these short- and long-term alterations in redox homeostasis. Downstream, GR and SF inhibited the activation of the redox-sensitive signaling cascades NF-κB (p65 and IKK) and MAPK ERK1/2, which contribute to inflammation and barrier permeabilization. GR (1 μM) and SF (0.5-1 μM) prevented TNFα-induced monolayer permeabilization and the associated reduction in the levels of the tight junction (TJ) proteins occludin and ZO-1. Both GR and SF also mitigated TNFα-induced increased mRNA levels of the myosin light chain kinase, which promotes TJ opening. Molecular docking suggests that although GR is mostly not absorbed, it could interact with extracellular and membrane sites in NOX1. Inhibition of NOX1 activity by GR would mitigate TNFα receptor downstream signaling and associated events. These findings support the concept that not only SF, but also GR, could exert systemic health benefits by protecting the intestinal barrier against inflammation-induced permeabilization, in part by regulating redox-sensitive pathways. GR has heretofore not been viewed as a biologically active molecule, but rather, the benign precursor of highly active SF. The consumption of GR and/or SF-rich vegetables or supplements in the diet may offer a means to mitigate the detrimental consequences of intestinal permeabilization, not only in disease states but also in conditions characterized by chronic inflammation of dietary and lifestyle origin.
All subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and additionally subjects will use the Kinesia-360™ wearable device at home while awake for continuous measurement of motor symptoms. The Investigator will use these symptom data to provide feedback to subjects on their motor symptoms and to supplement standard of care to titrate the optimal dose of Neupro for any given subject.
Sheep were among the first animals domesticated by humans, and to this day, small ruminants are primarily raised for their meat, milk, and wool. This study evaluated the goodness of fit for growth curve models using observed age and weight data from crossbred lambs of various breeds based on the mean values between paired breeds. We employed a hybrid metaheuristic algorithm, combining a simulated annealing (SA) algorithm and a genetic algorithm (GA) called SAGAC, to determine the optimal parameter values for growth models, ensuring the best alignment between simulated and observed curves. The goodness of fit and model accuracy was assessed using the coefficient of determination (R2), Mean Absolute Error (MAE), Root Mean Square Error (RMSE), and Mean Absolute Percentage Error (MAPE). Errors were measured by comparing the criteria differences between simulated and observed data. Thirty crossbreed combinations were simulated, considering the average weight. Analysis of the observed and simulated growth curves indicated that specific crossbreeding scenarios produced promising results. This simulation approach is believed to assist geneticists in predicting potential crossbreeding outcomes, thereby saving time and financial resources in field research.